 James Liu
Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Estrogens | 8 | 2020 | 346 | 2.620 |
Why?
| | Postmenopause | 6 | 2021 | 349 | 1.430 |
Why?
| | Leiomyoma | 3 | 2021 | 73 | 1.380 |
Why?
| | Norpregnadienes | 2 | 2021 | 7 | 1.350 |
Why?
| | Vaginal Creams, Foams, and Jellies | 2 | 2018 | 4 | 1.160 |
Why?
| | Dyspareunia | 2 | 2018 | 8 | 1.160 |
Why?
| | Vulva | 2 | 2018 | 24 | 1.150 |
Why?
| | Estrogen Replacement Therapy | 6 | 2020 | 137 | 1.110 |
Why?
| | Estradiol | 4 | 2021 | 493 | 1.070 |
Why?
| | Vagina | 4 | 2021 | 174 | 1.060 |
Why?
| | Ovary | 4 | 2020 | 207 | 0.850 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2023 | 50 | 0.800 |
Why?
| | Ovarian Neoplasms | 3 | 2020 | 484 | 0.760 |
Why?
| | Contraceptive Devices, Female | 1 | 2021 | 10 | 0.730 |
Why?
| | Pregnenediones | 1 | 2021 | 20 | 0.720 |
Why?
| | Hydrocarbons, Fluorinated | 1 | 2020 | 9 | 0.690 |
Why?
| | Hormone Antagonists | 1 | 2020 | 32 | 0.680 |
Why?
| | Menopause, Premature | 1 | 2020 | 9 | 0.680 |
Why?
| | Uterine Neoplasms | 2 | 2018 | 101 | 0.670 |
Why?
| | Salpingo-oophorectomy | 1 | 2020 | 18 | 0.670 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2018 | 154 | 0.650 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2020 | 204 | 0.600 |
Why?
| | Uterine Hemorrhage | 1 | 2018 | 33 | 0.600 |
Why?
| | Androgen Antagonists | 1 | 2019 | 78 | 0.600 |
Why?
| | Breast Neoplasms | 2 | 2020 | 2127 | 0.590 |
Why?
| | Hysterectomy | 2 | 2018 | 117 | 0.570 |
Why?
| | Vaginal Diseases | 1 | 2017 | 21 | 0.570 |
Why?
| | Osteoporosis | 1 | 2020 | 229 | 0.560 |
Why?
| | Pyrimidines | 1 | 2020 | 458 | 0.530 |
Why?
| | Cardiovascular System | 1 | 2018 | 136 | 0.520 |
Why?
| | Testosterone | 2 | 2019 | 372 | 0.520 |
Why?
| | Transgender Persons | 1 | 2019 | 172 | 0.500 |
Why?
| | Pituitary Neoplasms | 3 | 2015 | 179 | 0.430 |
Why?
| | Double-Blind Method | 6 | 2021 | 1874 | 0.430 |
Why?
| | Pneumocephalus | 1 | 2013 | 3 | 0.420 |
Why?
| | Reproductive Medicine | 1 | 2012 | 14 | 0.390 |
Why?
| | Female | 27 | 2023 | 68494 | 0.380 |
Why?
| | Estrogens, Conjugated (USP) | 1 | 2012 | 46 | 0.370 |
Why?
| | Endocrinology | 1 | 2012 | 74 | 0.360 |
Why?
| | Hot Flashes | 1 | 2012 | 82 | 0.360 |
Why?
| | Atrophy | 4 | 2021 | 169 | 0.350 |
Why?
| | Endoscopy | 1 | 2013 | 285 | 0.340 |
Why?
| | Adenoma | 2 | 2015 | 214 | 0.330 |
Why?
| | Sleep Deprivation | 1 | 2012 | 171 | 0.330 |
Why?
| | Humans | 30 | 2023 | 129144 | 0.290 |
Why?
| | Gonadotropins, Pituitary | 1 | 2007 | 22 | 0.270 |
Why?
| | Ovarian Hyperstimulation Syndrome | 1 | 2007 | 7 | 0.270 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 541 | 0.260 |
Why?
| | Follicle Stimulating Hormone | 1 | 2007 | 235 | 0.240 |
Why?
| | Postoperative Complications | 2 | 2015 | 2472 | 0.240 |
Why?
| | Administration, Intravaginal | 4 | 2021 | 16 | 0.240 |
Why?
| | Drainage | 2 | 2015 | 164 | 0.210 |
Why?
| | Craniotomy | 1 | 2023 | 67 | 0.200 |
Why?
| | Menopause | 2 | 2015 | 297 | 0.190 |
Why?
| | Wakefulness | 1 | 2023 | 120 | 0.190 |
Why?
| | Skull Base Neoplasms | 1 | 2022 | 25 | 0.190 |
Why?
| | Intraoperative Complications | 1 | 2023 | 129 | 0.190 |
Why?
| | Skull Base | 1 | 2022 | 45 | 0.190 |
Why?
| | Progesterone | 2 | 2021 | 245 | 0.190 |
Why?
| | Ethinyl Estradiol | 1 | 2021 | 17 | 0.180 |
Why?
| | Endometrium | 2 | 2015 | 56 | 0.180 |
Why?
| | Treatment Outcome | 5 | 2023 | 10192 | 0.180 |
Why?
| | Middle Aged | 10 | 2018 | 31050 | 0.180 |
Why?
| | Phytoestrogens | 1 | 2020 | 17 | 0.180 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2020 | 27 | 0.170 |
Why?
| | Contraceptive Agents | 1 | 2021 | 65 | 0.170 |
Why?
| | Genes, BRCA2 | 1 | 2020 | 24 | 0.170 |
Why?
| | Genes, BRCA1 | 1 | 2020 | 32 | 0.170 |
Why?
| | Drug Combinations | 1 | 2021 | 330 | 0.170 |
Why?
| | Seizures | 1 | 2023 | 401 | 0.160 |
Why?
| | Neuroprotection | 1 | 2019 | 38 | 0.160 |
Why?
| | Adult | 11 | 2023 | 35469 | 0.160 |
Why?
| | Pregnancy | 5 | 2021 | 6392 | 0.160 |
Why?
| | Amenorrhea | 1 | 2018 | 27 | 0.150 |
Why?
| | Pruritus Vulvae | 1 | 2018 | 1 | 0.150 |
Why?
| | Candidiasis, Vulvovaginal | 1 | 2018 | 4 | 0.150 |
Why?
| | Administration, Oral | 1 | 2020 | 785 | 0.140 |
Why?
| | Receptors, Progesterone | 2 | 2021 | 341 | 0.140 |
Why?
| | Administration, Topical | 1 | 2018 | 145 | 0.140 |
Why?
| | Symptom Assessment | 1 | 2018 | 125 | 0.140 |
Why?
| | Sinus Pericranii | 1 | 2016 | 1 | 0.140 |
Why?
| | Superior Sagittal Sinus | 1 | 2016 | 4 | 0.140 |
Why?
| | Transverse Sinuses | 1 | 2016 | 8 | 0.140 |
Why?
| | Cross-Over Studies | 1 | 2018 | 520 | 0.130 |
Why?
| | Decorin | 1 | 2015 | 7 | 0.120 |
Why?
| | Meningioma | 1 | 2016 | 81 | 0.120 |
Why?
| | Meningeal Neoplasms | 1 | 2016 | 92 | 0.120 |
Why?
| | Algorithms | 2 | 2015 | 1613 | 0.120 |
Why?
| | Peritoneum | 1 | 2015 | 41 | 0.120 |
Why?
| | Myometrium | 1 | 2015 | 37 | 0.120 |
Why?
| | Decision Making, Computer-Assisted | 1 | 2015 | 18 | 0.120 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2015 | 33 | 0.120 |
Why?
| | Proteoglycans | 1 | 2015 | 109 | 0.120 |
Why?
| | Diagnosis, Differential | 2 | 2011 | 1429 | 0.120 |
Why?
| | Product Labeling | 1 | 2014 | 6 | 0.120 |
Why?
| | Hormone Replacement Therapy | 1 | 2015 | 92 | 0.120 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2015 | 47 | 0.120 |
Why?
| | Endometriosis | 1 | 2015 | 46 | 0.120 |
Why?
| | Follow-Up Studies | 1 | 2023 | 4882 | 0.110 |
Why?
| | Optic Chiasm | 1 | 2013 | 18 | 0.100 |
Why?
| | Cerebral Ventricles | 1 | 2013 | 50 | 0.100 |
Why?
| | Fertility Agents, Female | 1 | 2012 | 19 | 0.100 |
Why?
| | Mobile Applications | 1 | 2015 | 160 | 0.100 |
Why?
| | Triptorelin Pamoate | 1 | 2012 | 19 | 0.100 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2012 | 34 | 0.100 |
Why?
| | Chorionic Gonadotropin | 1 | 2012 | 79 | 0.100 |
Why?
| | Cognition | 1 | 2019 | 1122 | 0.090 |
Why?
| | Pregnancy, Ectopic | 1 | 2012 | 52 | 0.090 |
Why?
| | Vasomotor System | 1 | 2012 | 44 | 0.090 |
Why?
| | Surgical Flaps | 1 | 2013 | 135 | 0.090 |
Why?
| | Spermatocidal Agents | 1 | 2010 | 7 | 0.090 |
Why?
| | Nonoxynol | 1 | 2010 | 4 | 0.090 |
Why?
| | Weight Reduction Programs | 1 | 2012 | 110 | 0.090 |
Why?
| | Betaine | 1 | 2010 | 75 | 0.090 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2010 | 97 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2736 | 0.080 |
Why?
| | Aged | 4 | 2018 | 21997 | 0.080 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 5382 | 0.080 |
Why?
| | Nose | 2 | 2022 | 63 | 0.080 |
Why?
| | Ovulation | 1 | 2008 | 40 | 0.070 |
Why?
| | Luteal Phase | 1 | 2008 | 44 | 0.070 |
Why?
| | Cohort Studies | 1 | 2018 | 5408 | 0.070 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2013 | 625 | 0.070 |
Why?
| | Retrospective Studies | 2 | 2023 | 14450 | 0.070 |
Why?
| | Male | 4 | 2023 | 63456 | 0.070 |
Why?
| | Quality of Life | 1 | 2018 | 2680 | 0.070 |
Why?
| | Gynatresia | 1 | 2006 | 1 | 0.070 |
Why?
| | Fertility | 1 | 2007 | 155 | 0.060 |
Why?
| | Infertility, Female | 1 | 2006 | 99 | 0.060 |
Why?
| | Surrogate Mothers | 1 | 2004 | 2 | 0.060 |
Why?
| | Mental Disorders | 1 | 2013 | 1028 | 0.060 |
Why?
| | Ovulation Induction | 1 | 2004 | 52 | 0.060 |
Why?
| | Embryo Transfer | 1 | 2004 | 33 | 0.060 |
Why?
| | Vasodilator Agents | 1 | 2006 | 326 | 0.060 |
Why?
| | Infertility | 1 | 2004 | 49 | 0.050 |
Why?
| | Piperazines | 1 | 2006 | 340 | 0.050 |
Why?
| | Ultrasonography | 1 | 2007 | 712 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2013 | 2511 | 0.050 |
Why?
| | Otolaryngologists | 1 | 2022 | 11 | 0.050 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2004 | 229 | 0.050 |
Why?
| | Risk Factors | 2 | 2015 | 9740 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2012 | 2045 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2016 | 3386 | 0.040 |
Why?
| | Biomarkers | 1 | 2012 | 3963 | 0.040 |
Why?
| | Neurosurgical Procedures | 1 | 2022 | 166 | 0.040 |
Why?
| | Obesity | 1 | 2012 | 2879 | 0.040 |
Why?
| | Artificial Intelligence | 1 | 2021 | 245 | 0.040 |
Why?
| | Aging | 1 | 2008 | 1774 | 0.040 |
Why?
| | Angiography, Digital Subtraction | 1 | 2016 | 43 | 0.030 |
Why?
| | Promegestone | 1 | 2015 | 33 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 2015 | 141 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 204 | 0.030 |
Why?
| | Income | 1 | 2015 | 188 | 0.030 |
Why?
| | Endometrial Neoplasms | 1 | 2015 | 162 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2015 | 388 | 0.030 |
Why?
| | Educational Status | 1 | 2015 | 469 | 0.030 |
Why?
| | Blotting, Western | 1 | 2015 | 1202 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1084 | 0.020 |
Why?
| | Societies, Medical | 1 | 2015 | 744 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2015 | 1678 | 0.020 |
Why?
| | Laparoscopy | 1 | 2015 | 449 | 0.020 |
Why?
| | Gels | 1 | 2010 | 81 | 0.020 |
Why?
| | Pregnanediol | 1 | 2008 | 12 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 3140 | 0.020 |
Why?
| | Estrone | 1 | 2008 | 37 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 3186 | 0.020 |
Why?
| | Decision Making | 1 | 2015 | 848 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 2368 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3372 | 0.020 |
Why?
| | Young Adult | 2 | 2015 | 12385 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2006 | 59 | 0.020 |
Why?
| | Sulfones | 1 | 2006 | 108 | 0.020 |
Why?
| | Purines | 1 | 2006 | 172 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2015 | 7037 | 0.010 |
Why?
| | Women's Health | 1 | 2006 | 364 | 0.010 |
Why?
| | Prospective Studies | 1 | 2015 | 7117 | 0.010 |
Why?
| | United States | 1 | 2015 | 13825 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2008 | 5044 | 0.010 |
Why?
| | Adolescent | 1 | 2010 | 20297 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|